Form 4: Kodiak Sciences Director Acquires 40,000 Stock Options
SEC Form 4 Filing
Bassil I. Dahiyat, a director of Kodiak Sciences Inc., acquired 40,000 stock options on June 28, 2024, exercisable at $2.35.
Summary
- On June 28, 2024, Bassil I. Dahiyat, a director of Kodiak Sciences Inc., acquired 40,000 stock options.
- The exercise price for these options is $2.35.
- The options vest on the earlier of June 28, 2025, or one day prior to the next annual meeting after the grant date, contingent on continued service as a board member.
- The options expire on June 27, 2034.
Sentiment
Score: 5
Explanation: The document is a neutral regulatory filing detailing a stock option grant. It doesn't inherently convey positive or negative sentiment.
Industry Context
This filing is a routine disclosure of stock option grants to a company director, which is a common practice in publicly traded companies to align the interests of management and shareholders.
Stakeholder Impact
- The stock option grant aligns the director's interests with those of the shareholders, potentially incentivizing actions that increase shareholder value.
Key Dates
| Date | Description |
|---|---|
| 06/28/2024 | Date of transaction: Director acquired 40,000 stock options. |
| 06/28/2025 | Earliest vesting date for the stock options, contingent on continued board service. |
| 06/27/2034 | Expiration date of the stock options. |
| 07/01/2024 | Date of Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.